Skip to main content
Qatalyst Partners M&A Case Study

Project Meridian — Special Committee Take-Private

A 5-hour Sell-Side M&A / Special Committee case study with a complete model answer

300
Minute Format
3
Deliverables
12
Concepts Tested
Advanced
Difficulty

Modeled After

Qatalyst Partners

Special committee discussion materials for a 2024 take-private of a US healthcare revenue-cycle company

Structure and exhibit set are modeled after Qatalyst Partners. The company, financials and proposal terms are entirely our own.

The Situation

Meridian Health Systems, Inc. (NASDAQ: MRDN) sells revenue-cycle management and provider-workflow software to hospital systems and large physician groups. It is headquartered in Northbrook, Illinois and employs roughly 4,100 people. The business has been performing: revenue grew 18.7% in FY2025 to $845 million, adjusted EBITDA reached $212 million on a 25.1% margin — up 34.2% year on year — and management's internal plan carries the company to $1,021 million of revenue and $276 million of adjusted EBITDA in CY2026E. The equity has not been rewarded for any of it. Meridian closed at $13.75 on January 22, 2026, against a 52-week high of $19.85 set the prior August and a low of $10.95 in November — a de-rating of roughly a third from high to unaffected while revenue was compounding at close to twenty percent.

Ridgeline Partners, a technology-focused private equity firm, has held 27.4% of Meridian since a 2022 PIPE whose documentation included a standstill. On January 23, 2026, Ridgeline asked the Board to waive that standstill; the request was disclosed on a Schedule 13D amendment, and the last close before it — January 22 — is the unaffected date. The Board granted the waiver on January 30, limited to a proposal made to the Special Committee. On February 9 Ridgeline delivered a non-binding proposal at $17.25 per share. On March 6 it raised to $18.50 per share in cash for the 72.6% of the company it does not own, structured as a one-step merger in which Ridgeline rolls its existing stake and minority holders take cash. The stock has since traded up to $16.20 as of March 13.

The Board formed a Special Committee of four independent, disinterested directors on January 26, with authority to evaluate, to negotiate and to reject, and to retain its own advisors; no transaction may be recommended to shareholders without the Committee's approval. The Committee has retained your firm as its financial advisor.

Be precise about what this transaction is, because the wrong label leads to the wrong analysis. Ridgeline is a significant minority holder, not a controller: 27.4% does not confer legal control on its face, and Meridian is not a "controlled company" under the Nasdaq rule, which requires more than half the voting power. This is a minority buy-in by a large existing holder, not a squeeze-out by a controlling company. The distinction changes which precedent transactions are the right comparison, because a third-party purchase of 100% of a company is a different transaction from an insider buying in the minority. And it changes the process advice, because a Committee that assumes it faces a controller will over-read its own weakness, while a Committee that assumes it faces an ordinary bidder will under-read the practical reality that Ridgeline holds a block, sits on the board, and is unlikely to sell into a competing deal. You are preparing the discussion materials for the Committee's meeting on March 14, 2026, and you have five hours.

Meridian Health Systems, Inc.

Sector
Healthcare IT — revenue-cycle management and provider-workflow software
Size
$845mm LTM revenue and $212mm LTM adjusted EBITDA (25.1% margin); $1,993.8mm equity value at the $13.75 unaffected price; ~4,100 employees
Geography
United States; headquartered in Northbrook, Illinois
Ownership
NASDAQ: MRDN. Ridgeline Partners holds 27.4% following a 2022 PIPE that carried a standstill — a significant minority stake, not a controlling one. Institutions other than Ridgeline hold 51.6% of shares outstanding, which is 71% of the 72.6% Ridgeline does not own. 138.6mm basic shares and 145.0mm diluted on a treasury stock method basis, with $520mm of gross debt and $195mm of balance sheet cash.
Situation
All-cash proposal at $18.50 per share from Ridgeline Partners, an existing 27.4% holder that would roll its stake rather than sell. A Special Committee of independent directors has been formed and has retained a financial advisor to evaluate the proposal, decide whether it warrants continued engagement, and determine what to counter.

The Prompt

You are an analyst supporting the Special Committee of the board of directors of Meridian Health Systems, Inc. Ridgeline Partners, which already owns 27.4% of Meridian, has proposed to acquire the shares it does not own for $18.50 per share in cash — up from an initial $17.25 proposal in February. The Committee meets in five hours and has asked for the analysis and discussion materials it needs to evaluate the proposal and decide how to respond.

Work in the blank Committee template. You have Meridian's last three years of public filings, management's current five-year plan, deal chronology and the 2022 PIPE documentation, market and trading data, and an unscreened data extract of comparable companies and transactions. Complete every tab of the workbook, then write the recommendation. Two things are graded as heavily as the arithmetic: the screening decisions you make on the raw extract, and the assumptions you choose — the valuation date's forward period, the discount rate and exit multiple ranges, the debt quantum, the price ladder columns and the return hurdles are yours to set and to defend, and none of them are supplied. The template charges stock-based compensation and says so on its row labels; that basis is given to you, and defending it is graded.

300 minutesMergers & AcquisitionsModeling

Supporting Materials

What you are handed at the start of the case, in the format a real process would use.

  • Meridian public filings summary

    PDF

    Three years of income statement, balance sheet and cash flow detail as a filer would present them — stock-based compensation and depreciation allocated to the functional expense lines and disclosed in the cash flow statement, acquired-intangible amortization shown separately — plus segment disclosure, the reconciliation of net income to adjusted EBITDA, and the capitalization table: 138.6mm basic and 145.0mm diluted shares, $520mm of gross debt, $195mm of balance sheet cash. FY2024A revenue of $712mm and adjusted EBITDA of $158mm; FY2025A revenue of $845mm and adjusted EBITDA of $212mm. The addback detail is here rather than summarized for you; read it before you accept adjusted EBITDA as the earnings base.

  • Management internal plan

    PDF

    The five-year Management Case as presented to the board — revenue from $1,021mm in 2026E to $1,363mm in 2030E, with adjusted EBITDA margins expanding from 27.0% to 29.5% — plus stock-based compensation, D&A split between core depreciation and acquired-intangible runoff, capex, working capital and the 25% tax rate needed to build unlevered free cash flow. Calendar-year periods only: there is no forward twelve-month column, because from a mid-March valuation date you have to calendarize one yourself.

  • Deal chronology and 2022 PIPE documentation

    PDF

    The January 23 standstill waiver request and its Schedule 13D amendment, the Board's January 26 formation of the Special Committee and its January 30 grant of the waiver, the February 9 proposal at $17.25, the March 6 revision to $18.50 and the conditions attached to each, the Committee's authorizing resolutions, and the standstill and information-rights provisions from the 2022 PIPE under which Ridgeline acquired its 27.4%. Read the dates in order and ask when each condition first appears.

  • Selected market and trading data

    PDF

    Daily trading history for Meridian around the January 22 unaffected date and the March 6 revised proposal, with 30-day, 60-day and 90-day VWAPs, the quarterly trading range, the 52-week range, average daily volume and value, and the ownership summary. Research coverage for the nine publishing analysts, with the ratings split, the $14.00 to $22.00 price target range against a $17.50 median, and consensus CY2026E revenue and adjusted EBITDA. It carries no comparable-company or precedent-transaction table: that data reaches you only through the raw extract, unscreened, because deciding what belongs in each set is part of the exercise.

  • Blank modeling template

    XLSX

    The Committee workbook with every tab, label, header and given assumption in place and every cell you are expected to produce left empty: Historical Financials is given in full and Assumptions & Inputs is given except for the 35 cells that are your own judgment, and Projections, Analysis at Various Prices, Sources & Uses, DCF, Comparable Companies, Precedent Transactions, Minority Buy-Ins, Football Field, Premiums Paid, and LBO & Ability to Pay are yours to build — 1,320 cells in all. Constituent names, observed multiple ranges, the discount rate and exit ranges, the debt quantum, the ladder columns and the return hurdles are blank, because the prompt asks you for them. Build in it and the exhibits come out in the format the Committee reads them in.

  • Selected companies and precedent transactions — raw extract

    XLSX

    The unformatted data pull behind the comparable-company and transaction tables: constituent-level trading statistics, enterprise values, deal terms and a footnote column carrying the raw descriptive detail on each name, as they come off the screen, before anyone has decided what belongs in the set. No medians, no means, no sorting. It carries more constituents than the analysis should use, including transactions that are not change-of-control events, and it publishes the minority buy-in transactions on their own sheet with each acquirer's pre-existing stake in a column. Screening the sets down, and being able to defend what you dropped and what you kept, is part of the work — one excludable row is enough to move the recommendation.

What You Have to Produce

The deliverables, in the order the committee will read them. The exercise runs 300 minutes.

  1. PART 1

    Projections and the forward period

    Complete the Projections tab: the five-year Management Case revenue build by segment, adjusted EBITDA and margin, stock-based compensation, D&A, capex and working capital, and unlevered free cash flow. Separate reported from organic growth in FY2026E and label which basis any growth rate you quote is on — the acquisition that closed mid-FY2025 makes the two materially different. Then derive the forward twelve-month column from the March 14, 2026 valuation date yourself; it is not supplied, and the calendar weighting is your judgment. Check the result against the periods on either side of it before any multiple is built off it.

  2. PART 2

    Discounted cash flow — Management Case and Street Case

    Build the DCF tab. The template strikes unlevered free cash flow AFTER stock-based compensation — say why that basis is defensible, and what adding it back and grossing the share count up would have changed. Build unlevered free cash flow on that basis for all five years. Choose the discount rate range and the terminal exit multiple range, and make sure the multiple is calibrated to the same earnings base your cash flows are struck on. Use the mid-year convention. Produce a discount rate by exit multiple sensitivity grid and disclose terminal value as a percentage of enterprise value on the face of the exhibit. Then run the same mechanics a second time on the Street's numbers rather than management's, and be prepared to say why a management-only case is a weakness in a conflicted deal.

  3. PART 3

    Comparable companies

    Screen the raw extract down to the peer set you will actually use and be able to defend every name you dropped. Build equity value, enterprise value, revenue and EBITDA multiples, growth and margin for each survivor, with median and mean. Restate the same peers on the same basis the DCF is struck on, after stock-based compensation — peer compensation intensity varies widely and does not track the adjusted multiple. Then place Meridian at $18.50 on both bases and say whether the position is deserved on growth and margin.

  4. PART 4

    Precedent transactions and the minority buy-in screen

    Screen the transaction extract and build the third-party change-of-control precedent set on both yardsticks, premium to unaffected and EV / LTM adjusted EBITDA, with median, mean, high and low. Expect the two yardsticks to rank the deals differently and say which governs. Then build the second screen the extract supports and the third-party set does not: transactions in which an existing significant holder bought in the minority. Deciding that Meridian needs that screen, constructing it, and reporting the observed move from first proposal to final price are graded parts of this case.

  5. PART 5

    Analysis at various prices

    Build the price ladder the Committee will negotiate from. Run the unaffected price, the current price and the $18.50 proposal as reference columns, bracketing the proposal, then illustrative prices above it in even steps — the columns are your choice. At each price show implied equity value and enterprise value off 145.0mm diluted shares, $520mm of debt and $195mm of cash; premiums to unaffected, to the 30-day VWAP, to current and to the 52-week high and low; and implied EV against LTM, forward and CY2026E revenue and adjusted EBITDA. Do not title the exhibit with a price that is not one of its columns.

  6. PART 6

    Sources and uses at the proposal

    Build sources and uses at $18.50: purchase of the fully diluted equity Ridgeline does not own, the rollover of Ridgeline's existing stake, repayment of the existing debt, transaction fees, cash applied against a minimum operating cash balance, and a reserve for appraisal cash — this is a cash merger, so every share not voted in favor carries an appraisal right and the cash has to be funded. Set the debt quantum yourself. Show pro forma gross and net leverage on more than one earnings basis, and quantify how much smaller Ridgeline's new equity check is than a third-party buyer's would be at the same price and the same debt.

  7. PART 7

    LBO and ability to pay

    Build the sponsor return model over a five-year hold: debt schedule with a cash sweep on beginning-of-period balances, exit equity value, a management incentive pool, multiple of money and IRR. Bridge the multiple of money into value from EBITDA growth, debt paydown and multiple expansion, and value leaked to management — a return leaning on multiple expansion is a weaker return and the exhibit must show it. Then solve for the maximum price at each of your chosen return hurdles, and state on the face of the exhibit what you assumed about the exit multiple as price flexes. Holding the exit multiple fixed while raising the entry price is a real convention, but it embeds multiple contraction, and an exhibit that does not disclose which convention it used is not usable.

  8. PART 8

    Football field and premiums paid

    Assemble the valuation summary. Every implied per-share range must be computed from the multiple range printed beside it, including a separate row for the minority buy-in screen and a separate row for the Street Case DCF. Shade reference-only methodologies — premiums paid, analyst targets, 52-week range — distinctly from the primary methodologies. Build premiums paid on both the third-party and the minority buy-in sets, applied to the unaffected price. Say where $18.50 sits within each range as a percentage of that range's width, and say where the evidence points in two directions.

  9. PART 9

    Recommendation to the Committee

    One page. Accept, reject, counter at a specific price, or authorize a market check. Give the number, and give the reservation price behind it. Name the yardstick the number rests on and the yardsticks that cut the other way. Then address the process: the standard of review this transaction will actually be judged under on its own chronology, and the conditions the Committee should require — the vote condition, the go-shop and its termination fee, matching rights, and information rights — distinguishing terms the buyer has proposed from terms you are asking for. Finally, name the one analysis you would want completed before the Committee commits.

How to Approach It

The order a strong candidate works in, and why. This is the shape of the answer — the finished answer deck, Excel model and memo are in the solution set below.

  1. 01

    Check the arithmetic is possible before you check that it foots

    The forward twelve-month column is the base of the entry multiple, the leverage and the comps positioning, so an error there propagates into everything. Derive it from the valuation date rather than accepting one, and then check that a forward period sits between the periods that bracket it. A forward figure outside its own brackets is impossible, and the fix is arithmetic rather than judgment.

  2. 02

    Defend the stock-based compensation basis, and carry it everywhere

    Meridian's stock-based compensation is a fifth of adjusted EBITDA and it is the single largest valuation judgment in the case. Two treatments are defensible — charge it as an operating cost and hold the share count, or add it back and dilute the count forward — and this template takes the first, which is why every cash flow row is struck after it. Doing both charges the cost twice; doing neither, which is what building unlevered free cash flow from adjusted EBIT does, charges it not at all. The work is knowing why the basis is defensible, what the other one would have moved, and then carrying it through to the terminal value — a multiple calibrated on one earnings base is meaningless applied to another.

  3. 03

    Fix the unaffected date before you compute a single premium

    Every premium in the deck is quoted off one number. The candidates are the close before the standstill waiver request, the day before the February proposal, and the current price. They are not interchangeable, and the gap between them is worth many points of headline premium. Pick one, write the reasoning on the page, and hold it across every exhibit.

  4. 04

    Screen the extract, then ask whether you have the right screen at all

    Excluding the constituents that do not belong is the first half of the work. The second half is noticing what the surviving set still cannot tell you: a set of third-party purchases of whole companies answers a question about control transactions, and the transaction in front of you is an insider buying in the minority. Building the second screen is a judgment nobody prompts you to make.

  5. 05

    Read the chronology as a term sheet, not as background

    The order of events determines the standard of review, which determines how much the process protections are worth and what you are really negotiating for. Note when the committee was formed, when the first economic proposal landed, and when each condition first appears in the record. If a full price round ran before a condition existed, the condition did not precede the negotiation, and a memo that says protections were in place from the outset is contradicted by documents that will be publicly filed.

  6. 06

    Convert the range into a decision, with a floor behind it

    The proposal will sit inside most of the methodologies, and that observation is not a recommendation. Name the action and the price, then name the reservation price behind it — a counter with no headroom is an ultimatum, and a Committee that opens at the number it would actually accept has nowhere to go. Pair the price with the process conditions the conflict requires, and be honest about which pieces of evidence cut against you.

Key Concepts

The ideas this case is built on. Know these cold and the case becomes a question of execution rather than knowledge.

Calendarizing a forward period

A valuation dated mid-year has a next-twelve-months window that straddles two fiscal years, so the forward column is built by weighting each year by the number of days of the window that fall in it. The weights are arithmetic. The judgment is the check afterwards: a forward figure has to sit between the two periods that bracket it, because a growing company cannot earn less over the next twelve months than it earns in the calendar year that window mostly overlaps. A forward figure below its own brackets is impossible however it was sourced, and because leverage, entry multiples and the trading-comparables position are all quoted off it, an error there reaches every exhibit before anyone notices.

Stock-based compensation in a DCF

Adjusted EBITDA adds stock-based compensation back, so unlevered free cash flow built from adjusted EBIT treats a large real cost as free. In software it is rarely small — here it runs above a fifth of adjusted EBITDA and above five percent of revenue — and the dilution is borne by exactly the shareholders the Committee represents. Two treatments are accepted: charge it as an operating expense and hold the share count constant, or add it back and gross the share count up for expected future issuance. The error is doing both, or neither, and not disclosing which. The consequence is large enough to move a recommendation, which is why the treatment belongs on the face of the exhibit rather than in the model's plumbing.

Terminal multiple basis

A terminal value is an earnings figure times a multiple, and the two have to be measured on the same basis. Peers are ordinarily quoted on adjusted EBITDA. If the forecast cash flows are struck after stock-based compensation but the exit multiple is lifted from peers quoted before it, the same cost is charged twice — once in the cash flows, again by applying an unadjusted multiple to a shrunken base — and the answer comes out spuriously low while looking conservative. The discipline is to restate the peer set on whatever basis the cash flows use, derive the multiple from that, and then translate the chosen range back onto the conventional basis as a sanity check that it lands somewhere a reasonable person would put it.

Terminal value concentration

The share of implied enterprise value that comes from the terminal value rather than the explicit forecast. In a growing software business it is routinely four-fifths or more, which means most of the answer rests on one multiple applied to one year that is several years out. That is not a reason to discard the DCF, but it is a reason to disclose the percentage on the exhibit and to refuse to let the DCF carry a recommendation alone. When a director asks how much confidence to place in a midpoint, the concentration figure is the honest first sentence of the answer.

Unaffected price

The share price before the market began to price in a potential transaction. Everything premium-related in a take-private deck is quoted against it, which is why the date is chosen carefully and disclosed on the page. Here the choice is between the last close before Ridgeline's standstill waiver request became public, the day before the first economic proposal, and the current price. The current price of $16.20 already contains the deal, so quoting a premium against it understates what minority holders are being offered for the standalone business. Advisors disclose the chosen date and the reasoning, because in litigation it is among the first things challenged.

Minority buy-in versus third-party change of control

A third-party buyer purchasing 100% of a company and an existing large holder buying in the minority are different transactions, and a precedent set made only of the former is the wrong yardstick for the latter. The third-party buyer must fund the whole equity, runs against a real auction, and pays a control premium. The insider rolls its stake, faces a committee rather than a market, and negotiates from a position no outside bidder occupies. Premiums and multiples in the two populations are not drawn from the same distribution, so a proposal that screens one way against control deals can screen the other way against buy-ins. Building both screens, and saying which one governs, is the analysis.

Premium versus multiple

A premium is a ratio to a market price and a multiple is a ratio to earnings, so they answer different questions and agree only by coincidence. In a real precedent set they routinely rank the deals differently — the most expensive deal on earnings need not be the most generous on premium. A premium inherits whatever was wrong with the price it is measured from: a stock that has de-rated on sector multiple compression will generate a flattering premium at a price that is not, on any earnings measure, generous. Showing both and explaining the disagreement is the work; averaging them, or quoting whichever supports the conclusion, is not.

Quality of earnings

The test of whether adjusted EBITDA is a number anyone should underwrite. Once total addbacks pass roughly a quarter of adjusted EBITDA, a credit committee starts discounting them, and the composition matters more than the total: a non-cash charge that is nonetheless a real economic cost is a different problem from a cash cost that recurs as long as the company keeps acquiring. So leverage is quoted on more than one basis — forward and trailing, adjusted and after the charges the adjustments removed — because quoting only the most flattering of the four is a choice everybody in the room can see.

Standard of review and the timing of conditions

A conflicted buy-in is reviewed under the demanding entire fairness standard unless it was conditioned from the outset on both an independent, empowered special committee and a non-waivable majority-of-the-minority vote — and outset means before substantive economic negotiation begins, not before signing. If a full price round ran before the vote condition appeared in the record, the conditions did not precede the negotiation and the protections do not shift the standard, however strong they look at signing. The advice usually does not change — negotiate hard, document everything, insist on the conditions — but what the Committee understands about how it will be judged does, and that is worth knowing before it commits.

Special committee

A committee of independent, disinterested directors formed to negotiate where the board, management or a large holder has a conflict. It retains its own advisors and negotiates at arm's length, and no transaction reaches shareholders without its approval. A committee can be constituted without having any power. What gives it power is the authority to reject, to hire its own bankers and counsel, and to control the process rather than react to it. In a conflicted deal the process is half the advice, and courts read the process backwards from the outcome.

Rollover equity

A holder converting an existing stake into equity of the post-transaction company instead of taking cash. Ridgeline's 27.4% — 39.7mm of the 145.0mm diluted shares — rolls rather than being purchased, so its new equity check is far smaller than the total equity funded, and each incremental dollar of price costs it materially less than it would cost a third-party buyer. A rolling holder is also buying the minority at a price it has to live with as an owner, so its incentives on price are not symmetric with an outside bidder's, and its ability to pay is a structural advantage rather than a return cushion.

Exit multiple convention in an ability-to-pay analysis

Solving for the maximum price a sponsor can pay at a target return requires an assumption about the exit multiple, and the two available conventions give different answers. Resetting the exit multiple to the entry multiple at every price is the standard no-expansion base case. Holding the exit multiple fixed at the multiple implied by the current proposal while raising the entry price is more conservative — but it embeds multiple contraction at every higher price, and an exhibit that does not say which convention it used is not interpretable. Showing both, and labeling them on the face of the page, is the only honest version.

Majority-of-the-minority and go-shop

The two conditions that give a conflicted buy-in its procedural credibility. A non-waivable majority-of-the-minority vote excludes the buyer and any rolling management from the count, so the minority decides. A go-shop, with a reduced termination fee during the window and matching rights limited to one round, tests the price against the market after signing rather than asserting it was tested — and the fee is the term that decides whether it is real or cosmetic, which makes it one of the few things a committee can move without touching price. Quote whose number any term is: the buyer's proposed fee and the fee you are asking for are different numbers and must never be presented as one.

Appraisal rights

In a cash merger every share not voted in favor carries a statutory appraisal right, and for a listed issuer paid in cash the market-out exception does not apply. The fair-value determination in an appraisal is not bounded by the merger price, and a holder base dominated by large institutions has the size and sophistication to petition. Appraisal cash is therefore a use of funds and has to be reserved in sources and uses; a funding table that omits it has understated what the buyer must fund.

What Makes It Hard

The specific traps in this case — the places candidates lose the assessment without noticing.

  • Which price the premiums are measured from decides the headline, and the case makes the wrong choice the easy one. The stock has run to $16.20 since the standstill waiver became public, so the current price is what sits on the screen when you start, and quoting the proposal against it produces a 14.2% premium. Against the January 22 close of $13.75 it is 34.5%; against the prior 30-day VWAP of $13.10 it is 41.2%. The reference is a judgment you have to make, defend on the page and then hold, because it does not stay in one exhibit — it propagates into the premiums paid comparison, the price ladder and the recommendation, and a deck that uses two different anchors in two different places will be caught.
  • The two precedent yardsticks disagree, and the disagreement is real rather than rhetorical. At $18.50 the premium to unaffected and the implied multiple of LTM adjusted EBITDA point in opposite directions relative to the set you screen, and both are correctly computed. The temptation is to average them, or to quote whichever supports the conclusion you have already reached. Neither is analysis. What the case asks is for you to work out what each ratio is actually measuring, decide which one governs here and why, and be willing to state on the page that the evidence points in two directions — including the part of it that cuts against your own recommendation.
  • The label you attach to the transaction changes which comparisons are valid. Ridgeline holds 27.4%, which is a large minority stake and not legal control, so the familiar controlling-holder shorthand is both wrong on the facts and analytically expensive, because it points you at the wrong precedent population. But treating the situation as an ordinary bidder approach is equally wrong: there is no auction to run against a holder of a quarter of the stock who has not said it would sell. Working out what the Committee's leverage actually consists of, which precedent population is the right comparison, and how the transaction should be structured given the gap between the legal label and the practical reality is the governance half of the assignment.
  • The sources and uses page and the returns model contain the negotiating argument, and both are usually built as compliance exhibits. Because Ridgeline rolls its stake rather than buying it, its incremental check per dollar of price is smaller than a third-party buyer's — but sizing that advantage is not the same as showing the buyer has a return cushion, and the two claims support very different recommendations. Whether there is room above $18.50, how much, and what kind of room it is, are questions the ability-to-pay analysis answers only if you are explicit about the assumptions inside it. Building the pages to prove the deal is financeable and moving on throws the point away.
  • 'Inside every range' is not a conclusion. The proposal will sit within the trading comparables, the precedents and the DCF, and the football field will show it. A football field displays uncertainty, and these ranges are wide enough that almost any price between the unaffected close and the 52-week high sits inside several of them. The Committee asked what to do at this meeting. A recommendation naming a specific action at a specific price, with a reservation price behind it, tied to the yardstick you argued should govern and paired with the conditions attached, is an answer; reporting that the proposal falls within the observed ranges is not.

Check Your Answer

Type the figures you produced and find out how many are right before you open the worked answer. You get a verdict and, where you are off, a pointer to the part of the build to re-check — never the number itself. Everything you type stays on this device.

How to type a figure. Digits, with an optional unit: 1,234.5, $1,234.5, 2.6x, 21.4%. For a negative use (20.0) or -20.0. Enter as many decimals as you carried — precision is never penalised.

Your Figures

  • a multiple — type 2.6 for 2.6x · graded within ±0.5%

  • $ in millions · graded within ±2%

  • $ in millions · graded within ±2%

  • $ in millions · graded within ±2%

  • $ in millions · graded within ±2%

  • $ in millions · graded within ±2%

  • $ in millions · graded within ±2%

  • $ in millions · graded within ±2%

  • $ in millions · graded within ±2%

  • $ in millions · graded within ±2%

  • $ in millions · graded within ±2%

  • percent — type 20.0 for 20% · graded within ±1%

What the Case Asked For

The arithmetic is only half of it. Tick off what you actually produced — this half is yours to score, because nothing can grade a written recommendation from a checkbox.

The Model Answer

The worked answer in full: answer deck, Excel model and memo, built the way a banker would actually build them. It is a reference, not a submission — a strong answer under the clock is far shorter.

What the Solution Covers

  • Discounted cash flow, including the treatment of stock-based compensation
  • Calendarizing an NTM period from a mid-year valuation date
  • Comparable company and precedent transaction screening
  • Minority buy-in versus third-party change-of-control precedents
  • Premiums paid analysis
  • Illustrative statistics at various prices
  • Sources & uses
  • LBO and sponsor ability to pay
  • Unaffected price analysis
  • Quality of earnings and leverage on multiple bases
  • Standard of review and special committee process
  • Board recommendation

Answer Deck

Full model answer, banker-formatted

Memo

The written recommendation and how it was reached

The Excel Model

The model is linked and tied out end to end — every schedule, every formula and every check, in the file itself.

Downloads are available to Diamond members

Excel Model and PowerPoint Deck and Memo (PDF) and Answer Deck (PDF) — yours to open, edit and rebuild

Upgrade

Walkthrough

A conversational walkthrough of how to approach the case under time pressure — where to start, what to cut, and how the recommendation gets defended.

Audio Walkthrough

How to approach Project Meridian — Special Committee Take-Private · read along with the transcript

Frequently Asked Questions

What is a special committee case study in an investment banking interview?

It is a case where you advise a committee of independent directors evaluating an acquisition proposal that carries a conflict — most often a bidder who is already a large shareholder, or a management-participating buyout. You produce the board materials: projections and a forward period, a DCF, comparable companies, precedent transactions, a ladder of illustrative statistics at various prices, sources and uses, an ability-to-pay analysis, a football field and a recommendation. It tests judgment about process and independence as much as valuation mechanics, which is why it appears in second rounds, superdays and take-home rounds rather than first rounds.

How should you allocate five hours across a special committee case?

The workbook is 1,320 cells across ten built tabs plus four documents to read, so the budget has to cover every tab or you will submit a package with holes in it. A workable split of the 300 minutes: 30 minutes reading the filings, the plan and the chronology, fixing the unaffected date and calendarizing the forward period; 25 screening the raw extract and deciding you need a second, minority buy-in screen; 20 on Projections; 45 on the DCF, both the Management and Street cases, including the stock-based compensation decision and the sensitivity grid; 25 on Comparable Companies including the restatement after stock-based compensation; 25 on Precedent Transactions and Minority Buy-Ins together; 30 on Analysis at Various Prices; 15 on Sources and Uses; 45 on the LBO and ability-to-pay solve, which is the longest single build; 20 on the Football Field and Premiums Paid, which are assembly rather than analysis once the inputs exist; and 20 writing the recommendation and rereading your own work. That is 300 minutes with nothing spare. The most common failure is spending an hour perfecting one exhibit and leaving three tabs empty.

Why does the choice of unaffected date matter so much?

Because every premium in the package is quoted off one number, and the candidates are far apart. Meridian closed at $13.75 on January 22, 2026, the last trading day before Ridgeline's standstill waiver request became public; it traded at $16.20 on March 13; the 30-day VWAP before the unaffected date was $13.10. The $18.50 proposal is a 34.5% premium against the first, 14.2% against the second and 41.2% against the third. Measuring a premium against a post-leak price asks minority holders to be grateful for a move they are being bought out of, and measuring it against too early a reference overstates what is being paid. Advisors disclose the chosen date and the reasoning on the page, because in litigation it is among the first things challenged.

How do you treat stock-based compensation in a take-private DCF?

Explicitly, and only one way at a time. Adjusted EBITDA adds it back, so a DCF that starts unlevered free cash flow from adjusted EBIT has assumed a large real cost is free — at Meridian it is above a fifth of adjusted EBITDA and above five percent of revenue, so the effect is big enough to move a recommendation. The two accepted treatments are to charge it as an operating expense and hold the share count constant, or to add it back and gross the share count up for expected future issuance. This case's template takes the first and labels every affected row accordingly, so the question you are answering is why that basis holds and what the other would have moved. Either way the terminal value has to be struck on the same earnings base and the exit multiple calibrated to peers struck on that base, or you charge the same cost twice. State the treatment on the exhibit; a reviewer who cannot tell which you used will assume the flattering one.

Is a 34.5% premium enough in a take-private?

Not on its own, and this case is built to show why. A premium is a ratio to a market price, so it imports whatever was wrong with that price. Meridian's unaffected close of $13.75 sits against a $19.85 52-week high set seven months earlier, in a year when revenue grew 18.7% and adjusted EBITDA grew 34.2% — so before you can read the premium you have to form a view on how much of that de-rating was sector multiple compression and how much was a permanent impairment of Meridian's earning power, because a de-rated starting point manufactures premium without manufacturing value. The other half of the answer is which population you are comparing against: premiums paid in third-party purchases of whole companies and premiums paid by existing holders buying in the minority are not the same distribution, and the proposal can screen differently against each.

How does it change the analysis when the buyer already owns 27.4% of the target?

In three ways, and the first is to be precise about what 27.4% is: a significant minority stake, not legal control, and not a controlled company under the Nasdaq threshold of more than half the voting power. First, the comparison set changes — the relevant precedents are minority buy-ins, not third-party change-of-control deals, and building that screen is part of the exercise. Second, the buyer's economics differ: rolling an existing stake means a smaller incremental check per dollar of price than a third-party buyer at the same price and the same debt, which is a structural advantage and not the same thing as a large return cushion. Third, the process is substantive advice rather than boilerplate — there is no realistic auction against a holder of a quarter of the stock, so the Committee's leverage is its power to say no, plus the conditions it can insist on, and the timing of those conditions relative to the price negotiation determines the standard of review the transaction is judged under.

What does the interviewer look for in the recommendation page?

A specific action, a number, a reservation price behind the number, the yardstick it rests on, the evidence that cuts the other way, the conditions attached, and an honest statement of what is still unknown. A strong page says whether to keep engaging, names the price to counter at and the floor below it, ties the price to the analysis that governs, concedes the yardsticks on which the proposal already screens fairly, recommends the process protections the conflict requires while distinguishing the buyer's proposed terms from the terms being asked for, and identifies the one piece of work to complete before the Committee commits. Pages that restate the preceding exhibits without reaching a decision score poorly no matter how clean the underlying work is — and so do pages that overstate the Committee's floor, because a Committee told its walk-away price is higher than it really is will negotiate badly.

About This Sell-Side M&A / Special Committee Case Study

Sell-Side M&A / Special Committee case study for investment banking interviews. 300-minute format covering discounted cash flow, including the treatment of stock-based compensation, calendarizing an ntm period from a mid-year valuation date, comparable company and precedent transaction screening. Includes the full prompt, a model answer deck, a tied-out Excel model, a written memo and an audio walkthrough.

This case study sits in Investment Banking, under Mergers & Acquisitions. Every case ships with the full prompt, the supporting materials, a complete model answer and an audio walkthrough of the judgment behind the recommendation.

300-Minute Format

The time limit a real assessment would give you

Answer Deck

Included in the model answer

Excel Model

Included in the model answer

Memo

Included in the model answer

Audio Walkthrough

How to approach the case under time pressure

200K+ students have used IB Vine to help land offers at top firms.

Moelis & Co.

umich.edu
Diamond Tier

I loved IB Vine. I’m going into Private Capital Advisory (PCA); you have the lessons on there for PCA and that was actually a game changer. I went into those interviews and knew about the core PCA concepts like net asset value, primary fundraising vs. secondary advisory, etc. I swear I was on IB Vine like a few hours a day. The opportunity to have that learning section and go through the questions people submit and everything — there’s no better tool out there. I loved the guides/lessons. The user interface is amazing. The way you’ve simplified it is so spectacular — it’s just so much easier to digest. It’s fun to use too; I’d rather use IB Vine than scroll through a guide. To be honest, I think the product is perfect. I genuinely owe you a big thanks.

Moelis & Co.

smu.edu
Diamond Tier

IB Vine is a tool we really love to use in the club I’m a part of, and there’s really no other resource like it. You guys do a phenomenal job with the question bank. I recruited specifically for Energy banking, and IB Vine was my most used resource for generalist questions (which were about 50% of my interview questions; the rest being Energy-specific); the majority of such questions I saw in interviews were at least similar (if not the same) to the ones on IB Vine.

Perella Weinberg

umich.edu
Diamond Tier

Once I read through the BIWS learning guides, I really didn’t refer to them again. I didn’t even really run through the 400 question guide once I found IB Vine, which I heard about through one of my classmates. We even get a free subscription (like most business schools) to Wall Street Prep, and if I’m being completely honest, I never even logged in to WSP. IB Vine is pretty much the only tool I used (along with our club question bank & mock interviews with peers) and it was invaluable for recruiting.

Cantor Fitzgerald

babson.edu
Diamond Tier

What a platform, made such a huge difference. I did superdays at Evercore, PJT, M. Klein and Barclays among others from a non-target school and did not miss a single technical in any interview process through prepping with IB Vine.

Barclays

ufl.edu
Pro Tier

Very accurate questions and all of the solutions are easy to follow. At least 10 of the questions I studied through this platform appeared in my Round 1 or Superday interviews.

TD Securities

umich.edu
Diamond Tier

THANK YOU SO MUCH IB VINE, I COULD NOT HAVE DONE THIS WITHOUT YOU, SERIOUSLY!!! IB Vine was the best website ever. I spent at least two hours on this daily (seriously) from October through I get my offer in February.

Citadel

uchicago.edu
Pro Tier

I’m doing public equities this summer and next. I know the name is “IB Vine” but at the undergrad level a lot of the technicals across public equities are the same as investment banking. I recommend your software to all my friends!

Piper Sandler

cmc.edu
Pro Tier

I loved this site! 1000% this is the best resource I used in the process.

Lazard

amherst.edu
Diamond Tier

This was the greatest tool ever. I genuinely enjoyed running through the technicals/behaviorals and it was very helpful!

Houlihan Lokey

wustl.edu
Diamond Tier

IB Vine was the most helpful resource I had during recruiting. I will continue to promote it to other students at WashU and elsewhere.

Jefferies

georgetown.edu
Diamond Tier

Awesome product, helped me crush my technicals in my interviews and land a great role. Thank you, seriously was a huge help.

Morgan Stanley

wharton.upenn.edu
Diamond Tier

Very helpful to get real-life questions unlike the 400 guide, especially for merger math. Built deeper understanding of key concepts.

Houlihan Lokey

princeton.edu
Diamond Tier

Extremely helpful study tool that carried me through the recruitment process from start to end.

Evercore

uchicago.edu
Diamond Tier

You guys are doing great work over there with IB Vine. Absolute staple for interview prep.

Rothschild

colorado.edu
Diamond Tier

IB Vine was incredibly helpful and I am forever thankful for all the help.

RBC

oberlin.edu
Diamond Tier

IB Mock was amazing - I used it for multiple hours. Also the flashcards and the lessons features on IB Vine were fantastic. Thank you!

Dragoneer

queensu.ca
Diamond Tier

IB Vine is such a great platform, really impressive. There is so much value in this. The audio podcasts / mock interview library are pretty incredible.

Case Study Preparation

Explore All Case Studies

100+ case studies, each with the full prompt, supporting materials and an audio walkthrough; most also ship a model answer deck and a tied-out Excel model.

Every case has a public page like this one. The member library is the signed-in index members work through.